Denali Therapeutics Inc. (DNLI) PT Raised to $87 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $21.25 +9.25%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $87.00 (from $77.00) while maintaining a Buy rating.
You May Also Be Interested In
- Denali Therapeutics Inc. (DNLI) PT Raised to $42 at Morgan Stanley
- Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
- Revvity Inc (RVTY) PT Raised to $177 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
